Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Medication is not primary treatment for personality disorder
Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Medication-related emergency
Suspected overdose, severe sedation, respiratory depression, seizure, serotonin toxicity, neuroleptic malignant syndrome, acute dystonia with airway compromise or dangerous withdrawal requires urgent medical treatment.
Action: Use ABCDE, establish the substances, doses and timing, check glucose and observations, and seek emergency toxicology or specialist advice. Do not induce vomiting; preserve packaging and prescription information, assess intentionality and safeguarding, and arrange psychosocial assessment alongside medical care when feasible.
Overview
Apply NICE recommendations that medication does not treat personality disorder itself, distinguish legitimate comorbidity prescribing from symptom-driven polypharmacy, and review crisis medicines, overdose risk, dependence and deprescribing collaboratively.
Medication does not correct an enduring pattern of self and interpersonal functioning. NICE states that drugs should not be used specifically for borderline personality disorder or for its individual associated symptoms and behaviours, and that antipsychotics should not be medium- or long-term treatment for that disorder. For antisocial personality disorder, pharmacological interventions should not routinely target the disorder or associated aggression, anger and impulsivity. These recommendations counter diagnostic prescribing, not access to appropriate treatment for a separate mental or physical condition.
Comorbidity prescribing starts with a defensible diagnosis. Establish whether symptoms meet criteria for depression, bipolar disorder, psychosis, PTSD, ADHD, substance dependence, sleep disorder or another condition, and treat according to the relevant guidance. Distinguish brief reactive distress from a sustained syndrome and review whether substances, withdrawal, physical illness or existing adverse effects explain the presentation. Continue psychological and social care; a prescription should not become the only response because suitable therapy is unavailable.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
PsychiatryOriginal SBA
Long-term antipsychotic use
A patient with borderline personality disorder has taken an antipsychotic for two years solely for emotional instability and has no psychotic or bipolar disorder. Which plan best follows NICE guidance?
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Before starting, agree one primary indication and measurable target, expected onset, duration or review point, adverse effects, interactions and a stop rule. Consider pregnancy, physical disease, cognition, driving, work, overdose toxicity, dependence, diversion and ability to use the regimen. Check the complete list across primary care, mental health, emergency services and private or remote prescribers. Nominate responsibility. Several clinicians responding independently to crises can create duplicated sedatives, contradictory instructions and uncontrolled repeat supply.
Crisis medicine is exceptional and does not replace crisis planning. NICE's borderline guideline describes cautious short-term prescribing only after considering non-drug options, with one medicine where possible, low misuse and overdose potential, minimal quantity, an agreed target and monitoring, and a stop plan. After the crisis, review benefit, adverse effects and safety and plan to stop medicine begun for the crisis, usually within one week. No universal crisis drug or dose is endorsed for personality disorder, and there is therefore no standard disorder-specific regimen.
Long-term review looks for unsupported polypharmacy, sedation, weight and metabolic effects, sexual dysfunction, anticholinergic burden, falls, cognitive impairment, dependence and emotional blunting. Ask what each drug means to the person and what they fear will happen if it changes. Deprescribing is prioritised, gradual when withdrawal is possible, coordinated and monitored against baseline symptoms and function. If the original indication remains valid, optimise that treatment rather than withdrawing simply because a personality diagnosis is present.
Key points
NICE advises that drug treatment should not be used specifically for borderline personality disorder or its individual behaviours and symptoms, including repeated self-harm, emotional instability and transient psychotic symptoms.
Antipsychotic medication should not be used as medium- or long-term treatment for borderline personality disorder, and medication should not routinely treat antisocial personality disorder or associated aggression, anger or impulsivity.
Diagnose and treat a comorbid disorder according to its own guidance within a coherent personality-disorder treatment programme rather than prescribing for vague distress.
Before prescribing, name the indication, target outcome, expected time course, stop rule, review date, adverse effects, interactions, overdose toxicity and misuse or dependence risk.
Review all current and recently stopped medicines, over-the-counter products, alcohol and drugs; avoid duplicating classes or adding a medicine to treat another medicine's adverse effect without reassessment.
Crisis prescribing, if used, should be cautious, time limited and integrated with the crisis plan; NICE expects a plan to stop medicine started in a borderline crisis, usually within one week.
Safer prescribing after self-harm may include smaller quantities, coordinated dispensing, limiting duplicate supplies and choosing lower-toxicity options for a genuine indication.
Aetiology
01
Symptom-driven prescribing
Pressure to relieve rapidly changing distress can lead to medication before syndrome, target, duration and non-drug options are adequately defined.
02
Fragmented responsibility
Several urgent and routine services may add or repeat medicines when no clinician owns reconciliation, monitoring and discontinuation.
03
Treatment-access gap
Medication can become a substitute when structured psychological and social interventions are delayed, unavailable or difficult to access.
Pathophysiology
1
Sedative burden
Additive central nervous system depression impairs alertness, memory, balance and inhibition and becomes more dangerous with alcohol, opioids or overdose.
2
Dependence and withdrawal
Neuroadaptation can produce tolerance and withdrawal, making continued use feel necessary and rapid reduction resemble worsening psychiatric illness.
3
Adverse-effect amplification
Weight change, akathisia, sexual dysfunction and cognitive slowing can worsen shame, agitation, relationships and adherence, generating further prescribing.
4
Overdose availability
Repeated or duplicated supplies increase accessible toxicity during periods when suicidal intent and impulse control may change quickly.
Clinical features and red flags
Diagnostic prescribing
A medicine is continued because a personality label appears in the record without a current target, evidence-based indication or accountable reviewer.
Crisis accumulation
New sedating medicines are added during successive emergencies without stopping previous trials, creating duplicate classes and unclear benefit.
Adverse-effect cascade
Fatigue, agitation, tremor, insomnia or weight gain caused by treatment is misread as new illness and prompts another prescription.
Overdose and misuse burden
High-toxicity agents, large quantities, several supply routes, stockpiling or dependence-forming medicines increase preventable harm during fluctuating crises.
Legitimate comorbid indication
A separate disorder is supported by its symptom pattern and course, with a specific target and review plan independent of the personality diagnosis.
Red flags requiring action
Unknown or mixed overdose, modified-release preparation, delayed-toxicity medicine or increasing drowsiness needs urgent poison-information and emergency assessment.
Several sedatives, opioids, alcohol or illicit drugs create additive respiratory, falls and cognitive danger even when each prescribed dose appears modest.
Abrupt cessation of a dependence-forming medicine, alcohol or sedative drug can cause severe withdrawal and requires a planned syndrome-specific approach.
Investigations
01Full medicines reconciliationFirst step
Why
Identify prescribed, over-the-counter, online, borrowed and illicit substances, recent changes and actual use.
Interpretation and limitations
Differences between lists, duplicate classes and intermittent high use can explain symptoms and reveal unsafe uncoordinated supply.
02Indication-by-indication review
Why
Link every medicine to a diagnosis, target, evidence, duration, benefit, harm and responsible prescriber.
Interpretation and limitations
Absent targets or no meaningful benefit after an adequate trial supports supervised discontinuation rather than automatic renewal.
03Physical adverse-effect assessment
Why
Evaluate sedation, movement, metabolic, cardiovascular, sexual, anticholinergic and organ-specific effects.
Interpretation and limitations
Examination and tests follow the actual medicine; adverse effects may worsen distress, self-image, adherence and daily function.
04Overdose and dependence assessment
Why
Review toxicity, quantities, access, stockpiling, alcohol or drug combinations, tolerance and withdrawal.
Interpretation and limitations
High burden prompts coordinated safer supply, method-specific withdrawal planning and reconsideration of the medicine's benefit.
05
Differential diagnosis
01
Comorbid mental disorder
A sustained depressive, psychotic, bipolar, trauma-related or neurodevelopmental syndrome may justify its own evidence-based pharmacological pathway.
02
Medication adverse effect
Akathisia, sedation, emotional blunting, withdrawal and anticholinergic symptoms may be mistaken for agitation, dissociation or personality-related distress.
03
Substance-related symptoms
Intoxication, dependence and withdrawal alter sleep, mood, perception and behaviour and can interact dangerously with prescribed treatment.
04
Physical health condition
Pain, endocrine disease, neurological illness and sleep disorders can generate psychiatric symptoms that require cause-specific assessment and care.
Management
01New prescriptionPrescribe for a defined disorderFirst stepMedication is considered because distress, insomnia, aggression, anxiety or unusual experiences are prominent.+
1Assess the time course and diagnostic criteria, substances, physical causes, current medicines and whether a comorbid disorder or emergency syndrome is actually present.
2AlternativeIf an indication is supported, agree the target, alternative options, benefit-harm balance, review time, stop rule, responsibility and safer quantity.
3Continue the psychological, social and crisis plan and document that the medicine treats the comorbid condition rather than personality disorder itself.
02Crisis useKeep exceptional prescribing briefNon-drug crisis measures are insufficient and short-term medication is being considered for a borderline personality crisis.+
1
Complications
01
Overdose and interaction
Toxic medicines, stockpiles and combinations with alcohol or drugs can cause respiratory failure, arrhythmia, seizure, organ injury or death.
02
Metabolic and neurological harm
Long exposure to some psychotropics can contribute to weight, glucose, lipid, movement and cardiovascular morbidity requiring active monitoring.
03
Dependence and difficult withdrawal
Tolerance, escalating use and withdrawal can restrict function, increase crisis presentations and complicate interpretation of underlying symptoms.
04
Delayed effective treatment
Symptom suppression and adverse effects may obscure formulation while structured psychological, social or comorbid care remains inaccessible.
Monitoring and follow-up
At every relevant review, record the indication, target, benefit, harm, adherence, duration, stop rule and clinician responsible for each medicine.
Monitor medicine-specific physical parameters and functional effects, including alertness, driving, work, weight, movement, sexual health and cognition.
Reassess overdose access, stockpiles, dispensing routes, alcohol or drug combinations, dependence and withdrawal after every self-harm or prescribing change.
Track access to structured psychological and social care so medication is not continued by default while the intended treatment remains unavailable.
During deprescribing, follow both withdrawal and recurrence of the original supported disorder, with clear contact and reinstatement criteria when clinically appropriate.
Special situations
No regimen is a message
The absence of a standard personality-disorder dose reflects guidance: prescribing requires a separate indication, not a universal symptom cocktail.
Comorbidity still deserves care
Refusing an indicated antidepressant, antipsychotic or physical-health medicine solely because personality difficulty exists is also diagnostic overshadowing.
One prescriber improves safety
Named coordination reduces duplicate supply, contradictory tapers and the addition of sedatives by clinicians who cannot see the full list.
Withdrawal can mimic relapse
Anxiety, insomnia, sensory symptoms and agitation after rapid reduction require timeline-based interpretation rather than immediate relabelling as personality crisis.
Deprescribing needs alliance
Acknowledging benefit, fear and prior service gaps makes a staged reduction safer and less likely to be experienced as punitive withdrawal.
Common pitfalls
01
Prescribing an antipsychotic long term for borderline personality disorder without a separate supported indication.
02
Using medicine routinely for antisocial personality-related aggression, anger or impulsivity.
03
Adding sedatives at repeated crises without reconciliation, targets, stop dates or one accountable prescriber.
04
Treating transient distress as a comorbid disorder without establishing duration, syndrome and impairment.
05
Stopping dependence-forming medicine abruptly or describing withdrawal symptoms as manipulative behaviour.
06
Withholding evidence-based medication for a genuine comorbid illness solely because personality difficulty is present.
Deprescribing is shared clinical work: prioritise highest-risk or unsupported medicines, discuss withdrawal and fears, reduce safely, and monitor the target problem and function.
Large repeat quantities, stockpiling, sharing, diversion or escalating use during crises should trigger immediate safer-prescribing and means-safety review.
Comorbidity reassessment
Why
Confirm whether the treated depression, psychosis, bipolar disorder or other condition remains supported.
Interpretation and limitations
A valid comorbid diagnosis justifies guideline-concordant treatment, while brief reactive symptoms alone should not sustain indefinite prescribing.
Review all substances, overdose and misuse risk, prior response and non-pharmacological options, and avoid multiple prescribers or duplicated sedatives.
2Where prescribing is justified, use one cautious time-limited plan with an explicit target, minimal quantity, monitoring and agreed discontinuation date.
3Review promptly after the crisis, stop if the target did not improve and plan to discontinue crisis medicine, usually within one week.
03Polypharmacy reviewDeprescribe collaboratively and safelySeveral medicines lack clear targets, cause harm or have accumulated across crisis contacts.+
1Reconcile actual use and rank medicines by immediate overdose, interaction, dependence and adverse-effect risk as well as evidence of benefit.
2Agree a staged reduction with the person and relevant prescribers, using an appropriate taper when withdrawal or relapse is possible and avoiding abrupt unsafe cessation.
3Monitor target symptoms, physical effects, sleep, function and crisis use, and revise the plan rather than replacing each stopped medicine automatically.